Telehealth Giant Launches Cheap Wegovy Knockoff Sparking Legal Battle

The $49 Challenge to Big Pharma

Hims & Hers announced Thursday it was offering a weight-loss pill with the same active ingredient as Novo Nordisk's Wegovy, starting at $49 per month, as part of its weight-loss solutions , dramatically undercutting Novo Nordisk's oral obesity medication that launched at $149 per month for cash-paying patients . The telehealth company's compounded semaglutide pill represents the latest salvo in an escalating battle between traditional pharmaceutical giants and upstart digital health platforms capitalizing on America's weight loss drug boom.

The Danish drugmaker responded to the news Thursday by vowing to sue Hims, calling the new product "an unapproved, inauthentic, and untested knockoff" of semaglutide . The announcement by Hims on Thursday put a dent in those plans, sinking its shares, as well as Lilly's, by more than 6% , demonstrating the immediate market impact of this pricing disruption.

Novo launched its Wegovy pill in the U.S. in early January, and CEO Mike Doustdar told CNBC on Wednesday that 170,000 people were already taking the medication . Now, just weeks after launch, the Danish pharmaceutical giant faces unexpected competition from a company that previously partnered with them before the relationship soured over similar compounding practices.

Legal Loopholes and Regulatory Gray Areas

Despite previous threats and warnings from the Food and Drug Administration, Hims has been able to keep its products on the market due to their status as compounded medications, a class of drugs that are customized and aren't subject to strict federal regulations . The practice is still permitted when a prescription is customized for the patient, and Hims and other companies say they offer "personalized" dosages and formulations of GLP-1 drugs that benefit patients .

Semaglutide's patent is protected in the U.S. until 2032, but Hims says its copies are "personalized," and therefore legal . "This compounded product uses a different formulation and delivery system than FDA-approved oral semaglutide," the company said , positioning their offering as a legitimate customization rather than a direct copy.

However, the regulatory environment is tightening. FDA head Martin Makary said the agency would take "swift action" against companies "mass-marketing illegal copycat drugs" , though he stopped short of naming specific companies. "The FDA cannot verify the quality, safety, or effectiveness of non-approved drugs," Makary said in his post .

The Technology Gap and Safety Concerns

Novo highlighted that it manufactures its Wegovy pill using so-called SNAC technology, which facilitates absorption when administered orally . It's not clear exactly how Hims' copy formula could match the level of absorption , raising questions about the effectiveness of the compounded alternative.

Novo took pains to differentiate its product, noting how it's the "only" company that manufactures an FDA-approved product and the compounded version "may contain impurities, unnecessary additives, and untested doses" . The company said all active pharmaceutical ingredients in compounded treatments are sourced exclusively from FDA-registered facilities, ensuring quality and safety , though this doesn't address absorption concerns.

In an investor call in London Thursday to present its full-year 2025 results, CEO Maziar Mike Doustdar said, "you're wasting $49, in my opinion," on Hims' compounded drug , reflecting the pharmaceutical industry's dismissive stance toward these alternatives.

Market Disruption and Future Implications

Over the last year or so, compounding pharmacies have used legal loopholes to capitalize on the widespread demand of GLP-1 medicines for weight loss. They first began producing lower-cost, copycat versions of injectable Wegovy and Eli Lilly's rival Zepbound when those drugs were in shortage . Now, with oral formulations entering the market, the competition is intensifying.

According to UBS Securities analyst Michael Yee's estimates, compounding prescriptions account for some 1 million of prescriptions compared to the 100 million or so his firm estimates being written across Novo and Lilly's GLP-1 franchises . While still a small fraction, this represents a significant revenue threat as more patients seek affordable alternatives.

The battle between Hims and Novo reflects broader tensions in American healthcare around drug pricing and access. As pharmaceutical companies face mounting pressure to reduce costs, telehealth platforms are positioning themselves as democratizing forces, offering cheaper alternatives through regulatory gray areas. Whether these compounded medications can deliver the same clinical outcomes as their FDA-approved counterparts remains an open question that will likely determine the future landscape of weight loss treatment in America.